
J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
JNJ halts Imaavy's rheumatoid arthritis program after trial results showed no added benefit over existing therapy.
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Nipocalimab combo therapy showed no added efficacy over anti-TNFα treatment in the Phase 2a trial. Johnson & Johnson ended the RA study but sees over $5 billion in potential for nipocalimab. Get a Year of Fast, Actionable Trade Alerts for 60% Off This Labor Day
Delhi, Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Global Market Current Size Insight In US$ Billion: 2022 - 2030 Global Market Opportunity: > US$ 90 Billion
Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
EXTON, PA, Aug. 26, 2025 ( GLOBE NEWSWIRE ) -- Patients with inflammatory bowel disease ( IBD ) in the US are taking a more active role than ever before in the decision to switch their advanced therapies, driving faster transitions between treatments and creating opportunities for brand growth, ...
- Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease ( IBD ) and potentially another autoimmune disease ...
- Aggregate net proceeds from private placement expected to fund SL-325 through multiple Phase 2 clinical trials, including in Inflammatory Bowel Disease ( IBD ) and potentially another autoimmune disease -
Zacks highlights gains for WisdomTree, SkyWest, and PepsiCo as its stock strategies deliver strong returns amid market volatility.
Johnson & Johnson stock surges above key moving averages as strong results, raised guidance and growth prospects fuel momentum.
Bridgewater Associates, the world's largest hedge fund, has completely liquidated its holdings in all U.S.-listed Chinese companies, a dramatic reversal that marks the firm's most significant strategic pivot under its new post-Ray Dalio leadership.
JPM, GS, JNJ, DIS, and MSFT are five blue-chip stocks that stand out with strong growth drivers and upgraded estimates as the Dow hits record highs.
Dr. Robert Lenz, Ms. Xin Liu and Dr. Sean Cao appointed to the Board of Directors Research and Development Committee established to accelerate innovation and long-term growth Dr. Ken Takeshita appointed to the Scientific Advisory Board
Pressure is mounting on the medical device maker.
If you're looking for income stocks, this trio of healthcare stocks is a great place to start with $500 (or $5,000).
These healthcare giants can survive the toughest challenges.
Massive growth stocks are driving the performance of the S&P 500, for better or for worse.
WARREN, N.J., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Tevogen Bio Holdings Inc. ( "Tevogen" or the "Company" ) ( Nasdaq: TVGN ) , announced today that it has been named in BINJE's BEST Health Care 2025: Companies, Organizations and Service Providers.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
AI-driven innovations in medical devices are fueling growth for BSX, JNJ, GEHC and TEM.
Johnson & Johnson JNJ is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs proposed by the Trump administration. J&J announced its investment on Thursday, as reported by Reuters.
These exchange-traded funds can provide a solid foundation for your portfolio.
Names you've heard of with track records to love.
Johnson & Johnson's JNJ short percent of float has fallen 6.58% since its last report. The company recently reported that it has 17.14 million shares sold short, which is 0.71% of all regular shares that are available for trading.
August 20, 2025 records indicate that Representative Thomas Kean filed a sale of Johnson & Johnson JNJ, valued between $31,003 and $115,000. According to the August filing, the transaction occurred on July 31, 2025. Currently, Johnson & Johnson shares are trading up 0.16% at $179.13.
J&J battles Stelara losses, talc lawsuits, tariffs and China headwinds while banking on growth plans and new launches to stay resilient.
According to an SEC filing published August 15, 2025, Sender Co & Partners, Inc. increased its position in Kenvue ( NYSE:KVUE ) by 530,717 shares. The estimated trade value, based on the period's average share price, was approximately $12.08 million.
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Aligos Therapeutics, Inc.
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ...
REDWOOD CITY, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Rezolute, Inc. RZLT ( "Rezolute" or the "Company" ) , a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism ( HI ) , today announced the appointment of Sunil Karnawat as Chief Commercial Officer, ...
CMS grants NTAP reimbursement of up to $21,125 for Carlsmed's spine implants. BofA forecasts 66% revenue growth in 2025, Buy rating with $16 target. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here → Carlsmed Inc.
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
SOMERSET, N.J., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Legend Biotech Corporation ( NASDAQ: LEGN ) ( Legend Biotech ) , a global leader in cell therapy, today announced the appointment of Carlos Santos as the Company's Chief Financial Officer, effective immediately.
Style Box ETF report for ...
These companies have successfully navigated similar obstacles before.
While it's been a consistent performer for decades, this company still has a massive growth opportunity.
These three dividend stocks offer steady income and a history of delivering through thick and thin.
The Vanguard Dividend Appreciation ETF has an excellent balance of growth, income, and value stocks.
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MeiraGTx Plc ( NASDAQ:MGTX ) , a biotechnology company specializing in gene therapies for neurodegenerative, ocular, and glandular disorders, released its second quarter results on August 14, 2025. The key news centered on a sizable year-over-year revenue gain ( GAAP ) -reflecting progress in ...
Palantir Technologies is priced for perfection. Unfortunately, no situation on Wall Street is ever perfect.
UTRECHT, The Netherlands, and PHILADELPHIA, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- LAVA Therapeutics N.V. ( NASDAQ: LVTX, "LAVA," or the "Company" ) , a clinical-stage immuno-oncology company historically focused on its proprietary Gammabody® bispecific gamma delta T cell engagers, today announced ...
REYKJAVIK, Iceland, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and ...
REYKJAVIK, Iceland, August 13, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first six months of 2025 and provided a summary of ...
Eli Lilly, CorMedix and Johnson & Johnson represent a diversified mix of healthcare stocks with bullish catalysts ...
HOUSTON, Aug. 13, 2025 /PRNewswire/ -- The ASCM Houston Chapter will host an exclusive professional development event, Navigating the Future - A Port of Houston Update, on Thursday, August 21, from 5:30 PM to 7:30 PM at the Houston Maritime Center & Museum, 2940 Riverby Road, Suite 200, Houston, ...
A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.
The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.